Proteome Regulatory News (PRM)

12 May 2023

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Proteome Sciences expands into the US: New Facility to open in San Diego

Proteome Sciences plc is pleased to announce the expansion of its proteomics services into the United States of America ("US"). A state of the art facility will be based in San Diego, California, to provide easy access to the established and growing pharmaceutical and biotechnology proteomics services requirements across the US and, in particular, the research hubs on the west coast. The Company's subsidiary, Proteome Sciences US Inc, has commenced staff recruitment and the new facility is expected to be fully operational in the fourth quarter of 2023.

Commenting on the new laboratory, Dr. Ian Pike, Chief Scientific Officer and President of Proteome Sciences US Inc. said "This is a major development for Proteome Sciences, building on the strong foundations of our services business in Europe. Whilst we already have an excellent customer base in the US, concerns over shipping costs, timing delays and customs delays have restricted the volume of orders that could be processed. We will now be able to provide a more accessible service to the rapidly growing pharma/biotech community across the US as the demand for proteomics services continues to expand."

Dr. Mariola Söhngen, Chief Executive Officer of Proteome Sciences plc, added "Internationalisation is a key element of our growth strategy. With a major part of our service and reagent business already focused over there, it is a logical step to establish our own facility for customers in the US. This is a real milestone for Proteome Sciences and we are looking forward to improving our service to the US marketplace with the San Diego facility opening later this year. "

For further information:

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.